{
    "clinical_study": {
        "@rank": "35122", 
        "arm_group": [
            {
                "arm_group_label": "CD0271 0.3% /CD1579 2.5% Gel", 
                "arm_group_type": "Experimental", 
                "description": "active arm"
            }, 
            {
                "arm_group_label": "CD0271 0.1% / CD1579 2.5%", 
                "arm_group_type": "Active Comparator", 
                "description": "Comparator arm"
            }, 
            {
                "arm_group_label": "Topical Gel Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo arm"
            }
        ], 
        "brief_summary": {
            "textblock": "The study hypothesis are based on the assumption that :\n\n        -  CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical\n           Gel Vehicle in the overall population and in the subgroup of severe Subjects\n\n        -  CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable\n           safety and tolerability profile"
        }, 
        "brief_title": "Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, who is 12 years of age or older at Screening visit.\n\n          2. Clinical diagnosis of acne vulgaris with facial involvement.\n\n          3. An IGA of Moderate (3) or Severe (4) at Baseline visit.\n\n          4. A minimum of 20 but not more than 100 inflammatory lesions (papules and pustules) on\n             the face (including the nose) at Baseline visit.\n\n          5. A minimum of 30 but not more than 150 non-inflammatory lesions (open comedones and\n             closed comedones) on the face (including the nose) at Baseline visit.\n\n        Exclusion Criteria:\n\n          1. More than 2 acne nodules on the face at Baseline visit.\n\n          2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.),\n             nodulo cystic acne, or acne requiring systemic treatment.\n\n          3. Underlying diseases or other dermatologic conditions that require the use of\n             interfering topical or systemic therapy or that might interfere with study\n             assessments such as, but not limited to, atopic dermatitis, perioral dermatitis or\n             rosacea. This includes clinically significant abnormal findings, uncontrolled or\n             serious disease, or any medical or surgical condition, that may either interfere with\n             the interpretation of the clinical trial results, and/or put the subject at\n             significant risk (according to Investigator's judgment) if he/she participates in the\n             clinical trial.\n\n          4. The subject has received, applied or taken some specified treatments within the\n             specified timeframe prior to the Baseline visit\n\n          5. The subject is unwilling to refrain from use of prohibited medication during the\n             clinical trial.\n\n          6. Use of hormonal contraceptives solely for control of acne."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "503", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01880320", 
            "org_study_id": "RD.06.SPR.18240"
        }, 
        "intervention": [
            {
                "arm_group_label": "CD0271 0.3% /CD1579 2.5% Gel", 
                "intervention_name": "CD0271 0.3% / CD1579 2.5%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CD0271 0.1% / CD1579 2.5%", 
                "intervention_name": "CD0271 0.1% / CD1579 2.5%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Topical Gel Vehicle", 
                "intervention_name": "Topical Gel Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Galderma Investigational site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Galderma Investigationnal Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hot Springs", 
                        "country": "United States", 
                        "state": "Arkansas"
                    }, 
                    "name": "Galderma investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Monica", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miramar", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newnan", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Galderma Investiogational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Snellville", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New-York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beachwood", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hershey", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Galderma investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goodlettsville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barrie", 
                        "country": "Canada"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Markham", 
                        "country": "Canada"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada"
                    }, 
                    "name": "Galderma Investiogational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peterborough", 
                        "country": "Canada"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surrey", 
                        "country": "Canada"
                    }, 
                    "name": "Galderma Investigational site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waterloo", 
                        "country": "Canada"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-center, Randomized, Double-blind, Parallel-group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of CD0271 0.3% / CD1579 2.5% Topical Gel Versus Topical Gel Vehicle in Subjects With Acne Vulgaris", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Public Health Agency of Canada", 
                "Russia: Ministry of Health of the Russian Federation"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Success rate is defined as the percentage of subjects with an IGA of clear or almost clear (and therefore at least a 2-grade improvement", 
            "measure": "Composite success rate", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01880320"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percent Changes in Inflammatory and Non-inflammatory Lesion Counts", 
            "safety_issue": "No", 
            "time_frame": "Week12"
        }, 
        "source": "Galderma R&D", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma R&D", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}